Insulin and Oral Hypoglycaemics in Gestational Diabetes
On this page
Direct answer
Insulin is the standard drug treatment for gestational diabetes when diet and exercise fail to reach glycaemic targets, because it barely crosses the placenta. Metformin and glibenclamide are accepted oral alternatives, with metformin generally preferred over glibenclamide, and both cross the placenta to some degree. Targets are a fasting glucose below 95 mg/dL and postprandial values below 140 mg/dL at one hour or 120 mg/dL at two hours.
What you must remember
- First step: nutrition therapy and activity for one to two weeks, unless fasting values are markedly raised at diagnosis.
- Targets: fasting below 95 mg/dL (5.3 mmol/L), one-hour postprandial below 140 mg/dL (7.8 mmol/L), two-hour postprandial below 120 mg/dL (6.7 mmol/L).
- Insulin: the reference standard; human or rapid-acting analogues are used in basal, prandial or premixed regimens, titrated to self-monitored glucose.
- Metformin: an oral alternative that crosses the placenta to a modest degree; neonatal data are broadly reassuring, but some women still need insulin added.
- Glibenclamide: an oral sulfonylurea that crosses the placenta and can stimulate fetal insulin release, so neonatal glucose needs checking after birth.
- Monitoring: capillary glucose profiles, fasting and after meals, are used to guide therapy, since HbA1c is less useful in pregnancy.
Choosing a regimen step by step
A woman whose fasting glucose stays high after diet changes needs a decision about medication. The steps below keep the choice consistent with the targets and the fetal risks, and each one feeds the next.
- Start with diet and activity: give nutrition counselling and daily activity for one to two weeks, then review the glucose diary.
- Check whether targets are met: compare fasting and postprandial values with the targets, and start medication if they are missed.
- Choose insulin or an oral agent: insulin is the reference standard, and metformin or glibenclamide is an acceptable alternative when insulin is declined or unsuitable.
- Titrate to the profile: adjust doses by self-monitored glucose, using basal insulin for raised fasting values and prandial dosing for isolated postprandial rises.
- Inform the neonatal team: record which drug was used, so that the newborn's glucose is checked after birth.
- Plan the timing of delivery: discuss timing with obstetric indications, since delivery in well-controlled disease is often planned near 39 weeks under current guidance.
Persistent fasting hyperglycaemia usually calls for basal insulin, while a rise confined to after meals responds to prandial dosing. Hypoglycaemia is the main risk of insulin, so patients need clear instructions on symptoms and treatment.
Where the exam tries to catch you
Vignettes describe a woman with raised glucose values and then test the order of decisions.
- Trap: starting insulin at once for every woman with gestational diabetes. Correct: diet and activity come first unless fasting values are markedly raised, and medication follows if targets are missed.
- Trap: treating oral agents as first-line in every case. Correct: insulin remains the reference standard, and oral agents are acceptable alternatives.
- Trap: ignoring the newborn after maternal glibenclamide. Correct: glibenclamide crosses the placenta, so the baby's glucose must be checked for hypoglycaemia.
- Trap: using random glucose or HbA1c as the treatment target. Correct: targets are fasting and postprandial capillary values.
Frequently asked questions
What fasting glucose target applies in gestational diabetes?
The usual fasting target in gestational diabetes is below 95 mg/dL, or 5.3 mmol/L. Postprandial targets are below 140 mg/dL at one hour and below 120 mg/dL at two hours, though national guidance may vary slightly.
Why is insulin preferred in gestational diabetes?
Insulin is preferred because it does not cross the placenta in meaningful amounts, so the fetus is exposed to very little drug. It remains the reference standard, and oral agents are used when insulin is declined or unsuitable.
Does metformin cross the placenta?
Metformin does cross the placenta to a modest degree, and it is an accepted oral alternative in gestational diabetes. Its neonatal safety data are broadly reassuring, though some women still need insulin added to reach their targets.
Why must the newborn be monitored after maternal glibenclamide?
Glibenclamide crosses the placenta and can stimulate fetal insulin release, so the newborn is at risk of hypoglycaemia after birth. The neonatal team therefore checks glucose in the first hours and days of life.